Accelerate Diagnostics (NASDAQ:AXDX) had its target price boosted by Piper Sandler from to in a note issued to investors on Tuesday, The Fly reports. The brokerage presently has an “overweight” rating on the medical research company’s stock.

AXDX has been the topic of a number of other reports. BidaskClub raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. lowered shares of Accelerate Diagnostics from a “neutral” rating to an “underweight” rating and set a $16.00 target price on the stock. in a report on Friday, September 27th. Finally, ValuEngine raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $19.00.

AXDX traded up $0.26 during trading on Tuesday, reaching $18.12. 235,565 shares of the company’s stock were exchanged, compared to its average volume of 173,721. Accelerate Diagnostics has a one year low of $14.27 and a one year high of $24.00. The company has a current ratio of 21.93, a quick ratio of 20.65 and a debt-to-equity ratio of 12.81. The stock has a market capitalization of $976.05 million, a PE ratio of -11.19 and a beta of 2.72. The firm has a fifty day moving average price of $16.59 and a two-hundred day moving average price of $18.03.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its earnings results on Thursday, November 7th. The medical research company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01. Accelerate Diagnostics had a negative net margin of 1,116.69% and a negative return on equity of 249.46%. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $3.15 million. Sell-side analysts expect that Accelerate Diagnostics will post -1.58 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Accelerate Diagnostics by 2.8% in the 3rd quarter. California State Teachers Retirement System now owns 43,159 shares of the medical research company’s stock worth $801,000 after purchasing an additional 1,164 shares during the period. Tower Research Capital LLC TRC bought a new stake in shares of Accelerate Diagnostics in the 2nd quarter worth $27,000. HighTower Advisors LLC grew its stake in shares of Accelerate Diagnostics by 28.5% in the 2nd quarter. HighTower Advisors LLC now owns 12,687 shares of the medical research company’s stock worth $289,000 after acquiring an additional 2,815 shares in the last quarter. SeaCrest Wealth Management LLC grew its stake in shares of Accelerate Diagnostics by 12.4% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 31,117 shares of the medical research company’s stock worth $578,000 after acquiring an additional 3,435 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Accelerate Diagnostics by 2.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 154,013 shares of the medical research company’s stock worth $3,524,000 after acquiring an additional 3,736 shares in the last quarter. Hedge funds and other institutional investors own 53.83% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Further Reading: Risk Tolerance

The Fly

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.